Arix Bioscience PLC (LON:ARIX) said investee company Autolus Therapeutics PLC (NASDAQ:AUTL) has published encouraging additional data from its phase I/II clinical study of a drug developed to treat a type of blood cancer called diffuse large B cell lymphoma.
AUTO3 is a next-generation programmed T cell therapy that is being trialled in people with relapsed or refractory (difficult to treat) forms of the disease.
The initial clinical readout from the trial revealed “encouraging clinical activity with a manageable safety profile”. The updated data continue to support “early indications of durability and high level of activity previously reported”, Autolus said in its statement.
The new information will be presented in full later today (Thursday, Jan 30) by Dr Martin Pulé, chief scientific officer of Autolus, at the EHA-EBMT 2nd European CAR T Cell Meeting held in Stiges, Spain.